

PRESS RELEASE



ExonHit will participate to the Paris Midcap Event on September 20 & 21

Paris, France – September 6, 2010 – ExonHit Therapeutics (Alternext: ALEHT), a fast emerging healthcare player developing innovative molecular diagnostic tests and therapeutics for Alzheimer's disease and cancer indications, today announced its participation to the tenth edition of the Midcap Event to be held in Paris on September 20 & 21, 2010.

The Midcap Event is a forum where institutional investors can meet with the management of mid-sized companies listed on NYSE Euronext. The conference will take place at the Palais Brongniart, 19 rue Notre-Dame des Victoires, 75 002 Paris.

ExonHit Therapeutics will be located at the ARKEON Finance stand. During these two days, fund managers will have the opportunity to meet with Loïc Maurel MD, President of the Management Board of ExonHit and Hervé Duchesne de Lamotte, Chief Financial Officer, to learn more about the Company, its latest developments and its strategic outlook for the remainder of 2010 and beyond.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for Alzheimer's disease and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com